(19)
(11) EP 1 196 444 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
06.08.2003 Bulletin 2003/32

(45) Mention of the grant of the patent:
04.06.2003 Bulletin 2003/23

(21) Application number: 00945656.7

(22) Date of filing: 12.07.2000
(51) International Patent Classification (IPC)7: C07K 14/575, A61K 38/22, A61K 47/48, A61P 3/10
(86) International application number:
PCT/DK0000/393
(87) International publication number:
WO 0100/4156 (18.01.2001 Gazette 2001/03)

(54)

EXENDIN-4 CONJUGATES AND THEIR MEDICAL USE

EXENDIN-4 KONJUGATE UND IHRE MEDIZINISCHE VERWENDUNG

CONJUGATES D'EXENDIN-4 ET LEUR UTILISATION MEDICALE

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 12.07.1999 US 143591 P
09.08.1999 EP 99610043

(43) Date of publication of application:
17.04.2002 Bulletin 2002/16

(60) Divisional application:
03005786.3 / 1329458

(73) Proprietor: Zealand Pharma A/S
2600 Glostrup (DK)

(72) Inventors:
  • LARSEN, Bjarne, Due
    DK-2700 Bronshoj (DK)
  • MIKKELSEN, Jens, Damsgaard
    DK-2800 Lyngby (DK)
  • NEVE, Soren
    DK-2800 Lyngby (DK)

(74) Representative: Kiddle, Simon John et al
Mewburn Ellis, York House, 23 Kingsway
London WC2B 6HP
London WC2B 6HP (GB)


(56) References cited: : 
WO-A-98/05351
WO-A-98/11126
WO-A-98/30231
WO-A-99/25727
WO-A-99/43708
 WO-A-98/08871
WO-A-98/22577
WO-A-99/07404
WO-A-99/25728
WO-A-99/46283
   
  • MEURER JANET A ET AL: "Properties of native and in vitro glycosylated forms of the glucagon-like peptide-1 receptor antagonist exendin (9-39)" BIOSIS, XP002146590
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).